Shares of Hims & Hers(NYSE: HIMS) fell as much as 15% on Thursday after news that Eli Lilly's(NYSE: LLY) GLP-1 drug was taken off the shortage list by the FDA. This could impact Hims & Hers' GLP-1 strategy, but it may not have the impact you think. In this video, Travis Hoium covers the day's news and why this isn't a big deal for investors.
*Stock prices used were end-of-day prices of Oct. 3, 2024. The video was published on Oct. 3, 2024.
Should you invest $1,000 in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $728,325!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of September 30, 2024
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
